Multi-center, Randomized, Open-label, Parallel-Arm, Single-dose, Pharmacokinetic Study of rVIIa-FP (CSL689) in Subjects With Congenital Factor VII Deficiency

Trial Profile

Multi-center, Randomized, Open-label, Parallel-Arm, Single-dose, Pharmacokinetic Study of rVIIa-FP (CSL689) in Subjects With Congenital Factor VII Deficiency

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs CSL 689 (Primary) ; Eptacog alfa
  • Indications Factor-VII-Deficiency
  • Focus Pharmacokinetics
  • Sponsors CSL Behring
  • Most Recent Events

    • 17 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 13 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
    • 13 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top